Propanc Biopharma

PPCB

Market cap $11M

MELBOURNE, Australia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for recurrent and metastatic cancer, today announced an update on corporate progress and reported financial results for the first quarter ended September 30, 2025 (Year end June 30). Corporate and R&D Highlights Advancing PRP Toward Phase 1b First-in-Human Trial (2026) Propanc continues to advance its lead candidate, PRP, toward a world-first Phase 1b clinical study in 30–40 patients with advanced solid tumors at the Peter Mac Cancer Center in Melbourne.

MELBOURNE, Australia, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new treatments for patients suffering from recurrent and metastatic cancer, today announced that it has entered into a securities purchase agreement with Hexstone Capital LLC ("Hexstone"), a family office that has invested in a significant number of Digital Asset Treasury (DAT) companies across a range of digital assets including BTC, ETH, SOL, DOGE, ATH, OG, and INJ. The agreement is for a private placement of up to $100 Million in convertible preferred stock and will be deployed to support its digital asset acquisition strategy and accelerate the Company's R&D pipeline, focusing on PRP entering a First-In-Human study second half of 2026.

We aim to leverage our public company platform to build a diversified digital asset portfolio while continuing to advance our innovative oncology pipeline.

This accelerates development of our clinical pipeline and leverages Hexstone's previous investments in companies that have built digital asset treasuries.

This accelerates development of our clinical pipeline and leverages Hexstone's previous investments in companies that have built digital asset treasuries.

Propanc announced its fiscal year-end following the filing of its annual 10-K report with the Securities and Exchange Commission on September 29, 2025.

MELBOURNE, Australia, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a certificate of grant for the Company's “proenzyme composition” patent was received from the US Patent & Trademark Office (USPTO).

Purchase of Ethereum will enhance a multi-faceted corporate strategy of cryptocurrency exposure, pharmaceutical drug development and asset acquisition.

Propanc is entering a transformational stage as it prepares for the advancement of its lead asset, “PRP”, to enter a Phase 1B, First-In-Human (FIH) study

MELBOURNE, Australia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that it closed an underwritten public offering of 1,000,000 shares of its common stock, par value $0.001 per share, at a price of $4.00 per share. The shares of common stock commenced trading on the Nasdaq Capital Market on August 15, 2025, under the ticker symbol, “PPCB”.